Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bellicum raises $55mm through oversubscribed Series C round

Executive Summary

Bellicum Pharmaceuticals Inc. (cell-based immunotherapies) raised $55mm through an oversubscribed Series C round. New investors RA Capital Management, Perceptive Advisors, Jennison Associates LLC, Sabby Capital, Ridgeback Capital Management, venBio Select, Redmile Group, LLC, AJU IB Investment, and three others participated, along with all of the company’s major returning investors including AVG Ventures and Remeditex Ventures. Jefferies & Co. was the placement agent. Some of the proceeds will fund development of BPX501, a Phase I/II controlled donor T-cell immunotherapy used in hematopoietic stem cell transplant in patients with leukemia or lymphoma, and also in cases of nonmalignant genetic diseases including severe combined immune deficiency, beta-thalassemia, sickle cell disease, and Fanconi anemia. Including the current round, Bellicum has raised $107mm since its 2004 inception.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies